Dopamine May Be a Safer Antiangiogenic Drug for Malignant Tumors
the Cancer Therapy Advisor take:
Vascular endothelial growth factor-A has a well-established role in tumor angiogenesis. Today, a variety of different cancer types and clinically treated via molecules that target vascular endothelial growth factor-A or its receptors.
The downside to the use of these antiangiogenic agents is that they are expensive and can produce serious adverse events in the patients who are being treated. It is necessary for researchers to focus on finding new drugs that have manageable risks and side effects in order to better to treat patients.
Researchers continued from the experimental model findings that revealed dopamine inhibits vascular endothelial growth factor-A-induced angiogenesis to investigate whether dopamine treatment produces toxicities that are similar to other antiangiogenic agents.
The researchers found that dopamine administered at 50 mg/kg/d x 7 days ip inhibited tumor angiogenesis and growth of both human colon cancer and lung cancer in mice without causing the typical side effects such as hypertension, hematological toxicities, renal toxicities, or hepatic toxicities.
Dopamine also prevented the development of neutropenia that is generally induced by 5-fluorouracil in the mice with colon cancer. Further research is need to confirm that the treatment is safe and effective in humans with these cancer types, but the promising results may indicate promise for the use of dopamine as a safer and more effective antiangiogenic drug for patients with cancer.

Vascular endothelial growth factor-A has a well-established role in tumor angiogenesis.
Related Resources
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Opinion: Understanding the FDA's Take on Cannabidiol
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer